Nuvation Bio (NUVB) Competitors $2.80 +0.10 (+3.70%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NUVB vs. IBRX, APLS, MLTX, PTCT, AGIO, HCM, MRUS, XENE, EWTX, and VRNAShould you be buying Nuvation Bio stock or one of its competitors? The main competitors of Nuvation Bio include ImmunityBio (IBRX), Apellis Pharmaceuticals (APLS), MoonLake Immunotherapeutics (MLTX), PTC Therapeutics (PTCT), Agios Pharmaceuticals (AGIO), HUTCHMED (HCM), Merus (MRUS), Xenon Pharmaceuticals (XENE), Edgewise Therapeutics (EWTX), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry. Nuvation Bio vs. ImmunityBio Apellis Pharmaceuticals MoonLake Immunotherapeutics PTC Therapeutics Agios Pharmaceuticals HUTCHMED Merus Xenon Pharmaceuticals Edgewise Therapeutics Verona Pharma Nuvation Bio (NYSE:NUVB) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment. Is NUVB or IBRX more profitable? Nuvation Bio has a net margin of 0.00% compared to ImmunityBio's net margin of -8,016.83%. ImmunityBio's return on equity of 0.00% beat Nuvation Bio's return on equity.Company Net Margins Return on Equity Return on Assets Nuvation BioN/A -21.89% -17.86% ImmunityBio -8,016.83%N/A -110.02% Does the media prefer NUVB or IBRX? In the previous week, ImmunityBio had 3 more articles in the media than Nuvation Bio. MarketBeat recorded 4 mentions for ImmunityBio and 1 mentions for Nuvation Bio. ImmunityBio's average media sentiment score of 0.20 beat Nuvation Bio's score of 0.15 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ImmunityBio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation and earnings, NUVB or IBRX? Nuvation Bio has higher earnings, but lower revenue than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvation BioN/AN/A-$75.80M-$2.17-1.29ImmunityBio$620K5,731.99-$583.20M-$0.92-5.54 Which has more volatility and risk, NUVB or IBRX? Nuvation Bio has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Does the MarketBeat Community prefer NUVB or IBRX? Nuvation Bio received 39 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 78.18% of users gave Nuvation Bio an outperform vote while only 16.00% of users gave ImmunityBio an outperform vote. CompanyUnderperformOutperformNuvation BioOutperform Votes4378.18% Underperform Votes1221.82% ImmunityBioOutperform Votes416.00%Underperform Votes2184.00% Do institutionals & insiders have more ownership in NUVB or IBRX? 61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 5.1% of Nuvation Bio shares are held by company insiders. Comparatively, 83.4% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate NUVB or IBRX? Nuvation Bio presently has a consensus target price of $6.60, indicating a potential upside of 135.29%. ImmunityBio has a consensus target price of $4.75, indicating a potential downside of 6.86%. Given Nuvation Bio's higher possible upside, equities analysts plainly believe Nuvation Bio is more favorable than ImmunityBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00ImmunityBio 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryNuvation Bio beats ImmunityBio on 10 of the 17 factors compared between the two stocks. Ad Golden CrestBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide Get Nuvation Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NUVB vs. The Competition Export to ExcelMetricNuvation BioPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$944.08M$6.99B$5.38B$20.15BDividend YieldN/A8.15%5.13%3.50%P/E Ratio-1.2911.05105.0444.55Price / SalesN/A361.961,233.1217.75Price / CashN/A52.5940.4121.28Price / Book1.8810.377.094.71Net Income-$75.80M$153.60M$119.65M$986.85M7 Day Performance6.65%4.60%2.25%3.76%1 Month Performance20.65%-6.29%-2.34%4.65%1 Year Performance122.62%33.41%33.97%27.72% Nuvation Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NUVBNuvation Bio2.3507 of 5 stars$2.81+3.7%$6.60+135.3%+122.6%$944.08MN/A-1.2960High Trading VolumeIBRXImmunityBio0.6284 of 5 stars$5.10+4.5%$4.75-6.8%+21.7%$3.55B$620,000.00-5.54590APLSApellis Pharmaceuticals4.6704 of 5 stars$28.01+1.9%$49.94+78.3%-35.4%$3.48B$396.59M-13.38702Analyst ForecastMLTXMoonLake Immunotherapeutics3.4714 of 5 stars$51.86+4.1%$79.00+52.3%+19.9%$3.31BN/A-38.432PTCTPTC Therapeutics2.5891 of 5 stars$42.89+2.2%$42.00-2.1%+100.0%$3.31B$937.82M-7.061,410Analyst DowngradeAGIOAgios Pharmaceuticals3.3042 of 5 stars$55.54+1.7%$52.33-5.8%+153.6%$3.17B$26.82M4.89390HCMHUTCHMED1.1761 of 5 stars$17.70-1.4%$20.55+16.1%-4.8%$3.09B$838M0.001,988News CoverageMRUSMerus3.0021 of 5 stars$44.64+4.0%$85.45+91.5%+92.4%$3.06B$43.95M-11.1037Analyst ForecastXENEXenon Pharmaceuticals3.5584 of 5 stars$39.97+1.6%$57.45+43.7%+43.2%$3.05B$9.43M-13.95251Insider TradeEWTXEdgewise Therapeutics2.7014 of 5 stars$32.10+0.4%$38.40+19.6%+404.7%$3.04BN/A-21.4060Analyst ForecastNews CoverageGap UpVRNAVerona Pharma2.6481 of 5 stars$38.01-2.2%$43.83+15.3%+176.2%$3.04B$460,000.00-19.7930Positive News Related Companies and Tools Related Companies ImmunityBio Alternatives Apellis Pharmaceuticals Alternatives MoonLake Immunotherapeutics Alternatives PTC Therapeutics Alternatives Agios Pharmaceuticals Alternatives HUTCHMED Alternatives Merus Alternatives Xenon Pharmaceuticals Alternatives Edgewise Therapeutics Alternatives Verona Pharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:NUVB) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvation Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvation Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
